Indicator of access to medicines in relation to the multiple dimensions of access
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Creation of a single indicator of access to medicines. Methods: Data collection was performed with individuals who obtained their medication from either public and/or private pharmacies. A Likert scale was used to measure the importance and satisfaction in relation to various access dimensions. Results: A total of 580 individuals were interviewed. Overall, participants attributed very similar importance scores to the dimensions of access to medicines. The results of the mean score of each dimension showed a statistically significant difference according to the type of pharmacy that the participant visited. Conclusion: This developed indicator will enable a review of access to medicines, making comparisons possible as well as improving decision making about public policies in the field of Pharmaceutical Services.
Supplementary Material
File (suppl_file.docx)
- Download
- 110.21 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Hogerzeil HV, Mirza Z. The World Medicines Situation Report, 2011. WHO, Switzerland (2011). http://apps.who.int/medicinedocs/documents/s20054en/s20054en.pdf?ua=1
2.
Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 373(9659), 240–249 (2009).
• Key reference outlining the importance of medicine costs especially in lower and middle income countries.
3.
Ofori-Asenso R, Agyeman AA. Irrational use of medicines – a summary of key concepts. Pharmacy 4, 35 (2016).
4.
Abiye Z, Tesfaye A, Hawaze S. Barriers to access: availability and affordability of essential drugs in a retail outlet of a public health center in south western Ethiopia. J. Appl. Pharm. Sci. 3(10), 101–105 (2013).
5.
Alsairi R. Access to medicine in developing countries. Am. J. Med. Med. Sci. 7(6), 271–276 (2017).
6.
Guan X, Hu H, Man C, Shi L. A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals. Int. J. Equity Health 17(1), 158 (2018).
• Interesting paper discussing the availability of essential medicines in different regions in China.
7.
Alefan Q, Amairi R, Tawalbeh S. Availability, prices and affordability of selected essential medicines in Jordan: a national survey. BMC Health Serv. Res. 18(1), 787 (2018).
8.
Putrik P, Ramiro S, Kvien TK et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann. Rheum. Dis. 73(1), 198–206 (2014).
9.
Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front. Pharmacol. 10, 279 (2019).
•• Good paper discussing the differences in the availability of biological medicines among European countries depending on issues of affordability and copayments.
10.
Kostic M, Djakovic L, Sujic R, Godman B, Jankovic SM. Inflammatory bowel diseases (Crohn's disease and ulcerative colitis): cost of treatment in Serbia and the implications. App. Health Econ. Health Pol. 15(1), 85–93 (2017).
11.
Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol. 1, 141 (2010).
12.
Garuoliene K, Godman B, Gulbinovic J, Schiffers K, Wettermark B. Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies. Expert Rev. Pharmacoecon. Outcomes Res. 16(2), 149–152 (2016).
13.
Markovic-Pekovic V, Skrbic R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev. Pharmacoecon. Outcomes Res. 12(5), 661–671 (2012).
14.
Gammie T, Lu CY, Babar ZU. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PloS One 10(10), e0140002 (2015).
15.
EURODIS. Breaking the Access Deadlock to Leave No One Behind. A contribution by EURORDIS and its Members on possibilities for patients' full and equitable access to rare disease therapies in Europe (2018). http://download2.eurordis.org.s3.amazonaws.com/positionpapers/eurordis_access_position_paper_final_4122017.pdf
16.
Kwon H-Y, Kim H, Godman B. Availability and affordability of drugs with a conditional approval by the European Medicines Agency; comparison of Korea with other countries and the implications. Front. Pharmacol. 9, 938 (2018).
17.
Chivukula MV, Tisocki K. Approaches to improving access to essential cancer medicines in the WHO south-east Asia Region. WHO South East Asia J. Public Health 7(2), 62–66 (2018).
18.
Saqib A, Iftikhar S, Sarwar MR. Availability and affordability of biologic versus non-biologic anticancer medicines: a cross-sectional study in Punjab, Pakistan. BMJ Open 8(6), e019015 (2018).
19.
Sarnola K, Ahonen R, Martikainen JE, Timonen J. Policies and availability of orphan medicines in outpatient care in 24 European countries. Eur. J. Clin. Pharmacol. 74(7), 895–902 (2018).
20.
Laxminarayan R, Matsoso P, Pant S et al. Access to effective antimicrobials: a worldwide challenge. Lancet 387(10014), 168–175 (2016).
21.
Simoens S, Sinnaeve PR. Patient co-payment and adherence to statins: a review and case studies. Cardiovasc. Drugs Ther. 28(1), 99–109 (2014).
22.
Nielsen JO, Shrestha AD, Neupane D, Kallestrup P. Non-adherence to anti-hypertensive medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 subjects. J. Hum. Hypertens. 31(1), 14–21 (2017).
23.
Chipwaza B, Mugasa JP, Mayumana I, Amuri M, Makungu C, Gwakisa PS. Self-medication with anti-malarials is a common practice in rural communities of Kilosa district in Tanzania despite the reported decline of malaria. Malaria J. 13(1), 252 (2014).
24.
Wirtz VJ, Kaplan WA, Kwan GF, Laing RO. Access to medications for cardiovascular diseases in low- and middle-income countries. Circulation 133(21), 2076–2085 (2016).
• Interesting paper discussing ways to enhance access to CV medicines in lower and middle income countries.
25.
Vasheghani Farahani A, Salamzadeh J, Rasekh HR, Najafi S, Mosadegh V. The availability and affordability of cardiovascular medicines for secondary prevention in Tehran province (Iran). Iran J. Pharm. Res. 17(Suppl.), 64–72 (2018).
26.
The Pan American Health Organization (PAHO). Access to high-cost medicines in the Americas: situation, challenges and perspectives. The Pan American Health Organization, Ministry of Health; Ministry of External Relations (2010). http://apps.who.int/medicinedocs/documents/s19112en/s19112en.pdf
27.
Caires de Souza AL, de Assis Acurcio F, Guerra Junior AA, Rezende Macedodo Nascimento RC, Godman B, Diniz LM. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. App. Health Econ. Health Pol. 12(1), 19–32 (2014).
28.
Teodoro C, Caetano R, Godman B et al. Federal procurement of unlicensed medicines in Brazil; findings and implications. Expert Rev. Pharmacoecon. Outcomes Res. 17(6), 607–613 (2017).
29.
De Oliveira GL, Guerra Junior AA, Godman B, Acurcio FA. Cost–effectiveness of vildagliptin for people with Type 2 diabetes mellitus in Brazil; findings and implications. Expert Rev. Pharmacoecon. Outcomes Res. 17(2), 109–119 (2017).
30.
Spivey P, Godman B. Health system perspectives. In: Drug Utilization Research: Methods and Applications. Elseviers M, Wettermark B, Almarsdóttir ABet al. et al. (Eds). Wiley, Oxford, UK (2016).
31.
Elseviers M, Vrijens B. Assessment of medication adherence in field research. In: Drug Utilization Research: Methods and Applications. Elseviers M, Wettermark B, Almarsdóttir ABet al. et al. (Eds). Wiley, UK (2016).
32.
Wirtz VJ, Hogerzeil HV, Gray AL et al. Essential medicines for universal health coverage. Lancet 389(10067), 403–476 (2017).
•• Landmark paper discussing essential medicines for universal health coverage.
33.
WHO. Equitable access to essential medicines: a framework for collective action. WHO, Geneva, Switzerland (2004). http://whqlibdoc.who.int/hq/2004/WHO_EDM_2004.4.pdf
34.
Mbui JM, Oluka MN, Guantai EM et al. Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications. Expert Rev. Clin. Pharmacol. 10(11), 1263–1271 (2017).
35.
Sandoz – A Novartis Division. Kenya is first country to launch ‘Novartis Access’, expanding affordable treatment options against chronic diseases (2015). www.sandoz.com/news/media-releases/kenya-first-country-launch-novartis-access-expanding-affordable-treatment
36.
Alvares J et al. Are we really measuring access? Systematic review of access measures to medicines in Brazil. Revista Brasileira de Pesquisa em Saúde 17(4), 138–155 (2015).
•• Good review discussing access to medicines in Brazil.
37.
Penchansky R, Thomas JW. The concept of access: definition and relationship to consumer satisfaction. MedCare 19(2), 127–140 (1981).
38.
Aday LA, Andersen R. Development of Indices of Access to Medical Care. Health Administration Press, MI, USA (1975).
39.
Bigdeli M, Jacobs B, Tomson G et al. Access to medicines from a health system perspective. Health Policy Plan. 28(7), 692–704 (2013).
40.
Guerra AA Jr, Acúrcio Fde A, Gomes CA et al. Availability of essential drugs in two regions of Minas Gerais, Brazil. Rev. Panam. Salud Publica 15(3), 168–75 (2004).
41.
Nascimento RCRMD, Álvares J, Guerra AA Jr et al. Availability of essential medicines in primary health care of the Brazilian Unified Health System. Rev. Saude Publica 51(Suppl. 2), 10s (2017).
•• Good paper discussing current access to medicines in ambulatory care in Brazil.
42.
Helfer AP, Camargo AL, Tavares NUL, Kanavos P, Bertoldi AD. Affordability and availability of drugs for treatment of chronic diseases in the public health care system. Rev. Panam. Salud Publica 31(3), 225–232 (2012).
43.
Barreto MN, Cesse EA, Lima RF et al. Analysis of access to hypertensive and diabetic drugs in the Family Health Strategy, State of Pernambuco, Brazil. Rev. Bras. Epidemiol. 18(2), 413–424 (2015).
44.
Barreto JL, Guimarães Mdo C. Evaluation of decentralized management of basic pharmaceutical care in Bahia State, Brazil. Cad. Saúde Pública 26(6), 1207–1220 (2010).
45.
Barbosa MM, Garcia MM, Nascimento RCRM et al. Infrastructure evaluation of Pharmaceutical Services in the National Health System of Minas Gerais. Cien Saude Colet. 22(8), 2475–2486 (2017).
• Interesting paper discussing the infrastructure of pharmaceutical services in Brazil.
46.
Minas Gerais. SECRETARIA DE ESTADO DE SAÚDE. SUPERINTENDÊNCIA DE ASSISTÊNCIA FARMACÊUTICA. Rede farmácia de Minas. Plano estadual de estruturação da rede de assistência farmacêutica: uma estratégia para ampliar o acesso e o uso racional de medicamentos no SUS. Belo Horizonte: SES-MG, 112 (2008).
47.
Nezenega ZS, Gacho YHM, Tafere TE. Patient satisfaction on tuberculosis treatment service and adherence to treatment in public health facilities of Sidama zone, South Ethiopia. BMC Health Serv. Res. 13(1), 110 (2013).
48.
Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open 3(1), pii: e001570 (2013).
49.
Farhat R, Assaf J, Jabbour H et al. Adherence to oral glucose lowering drugs, quality of life, treatment satisfaction and illness perception: a cross-sectional study in patients with Type 2 diabetes. Saudi Pharm. J. 27(1), 126–132 (2019).
50.
Bochenek T, Abilova V, Alkan A et al. Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian countries. Front. Pharmacol. 8, 942 (2017).
51.
Access to Medicine Foundation. Shortages, stockouts and scarcity (2018). https://accesstomedicinefoundation.org/media/atmf/Antibiotic-Shortages-Stockouts-and-Scarcity_Access-to-Medicine-Foundation_31-May-2018.pdf
52.
Sanchez RM, Ciconelli RM. The concepts of health access. Rev. Panam. Salud Publica 31(3), 260–268 (2012).
53.
Meyer JC, Schellack N, Stokes J et al. Ongoing initiatives to improve the quality and efficiency of medicine use within the public healthcare system in South Africa: a preliminary study. Front. Pharmacol. 8, 751 (2017).
54.
Costa JO, Almeida-Brasil CC, Godman B et al. Implementation of clinical guidelines in Brazil: should academic detailing be used? J. Pharm. Health Services Res. 7, 105–15 (2016).
55.
Do Nascimento R, Guerra AA Jr, Alvares J et al. Statin use in Brazil: findings and implications. Curr. Med. Res. Opin. 34(10), 180917 (2018).
• Good paper discussing current statin use in ambulatory care in Brazil including issues of availability.
56.
Agencia Nacional de Saúde Complementar (ANS). Caderno de Informação da Saúde Suplementar: beneficiários, operadoras e planos [Supplementary Health Information Booklet: beneficiaries, operators and plans]. ANS, Rio de Janeiro, Brazil (2017).
57.
Flawed but fair: Brazil's health system reaches out to the poor. WHO, Geneva, Switzerland (2008). www.who.int/bulletin/volumes/86/4/08-030408/en/
58.
da Silva WC, de Araujo VE, Lima E et al. Comparative effectiveness and safety of monoclonal antibodies (bevacizumab, cetuximab, and panitumumab) in combination with chemotherapy for metastatic colorectal cancer: a systematic review and meta-analysis. BioDrugs 32(6), 585–606 (2018).
59.
Dos Santos JB, Almeida AM, Acurcio FA et al. Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. J. Comp. Eff. Res. 5(6), 539–549 (2016).
60.
Barbosa WB, Costa JO, de Lemos LLP et al. Costs in the treatment of schizophrenia in adults receiving atypical antipsychotics: an 11-year cohort in Brazil. App. Health Econ. Health Pol. 16(5), 697–709 (2018).
61.
Roberts MJ, Hsiao W, Berman P. Getting Health Reform Right: A Guide to Improving Performance and Equity. Oxford University Press, Oxford, UK (2008).
62.
Fegg MJ, Kramer M, L'hoste S, Borasio GD. The Schedule for Meaning in Life Evaluation (SMiLE): validation of a new instrument for meaning-in-life research. J. Pain Symptom Manage. 35(4), 356–364 (2008).
63.
Moimaz SAS, Marques JAM, Saliba O, Garbin CAS, Zina LG, Saliba NA. Satisfaction and perception of SUS's users about public health care. Physis 20(4), 1419–1440 (2010).
64.
Frenk J. Concept and measurement of accessibility. Salud Publica Mex. 27(5), 438 (1985).
65.
United Nations Development Group. Indicators for Monitoring the Millennium Development Goals. United Nations, NY, USA (2003).
66.
WHO. How to Develop and Implement a National Drug Policy, 2nd Edition. WHO, Geneva, Switzerland (1988). http://apps.who.int/medicinedocs/pdf/s2283e/s2283e.pdf
67.
Likert R. A technique for the measurement of attitudes. Arch. Psychol. 140, 1–55 (1932).
68.
Godoi IP, Santos AS, Reis EA et al. Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia[R]) in Brazil; implications for future pricing considerations. Front. Pharmacol. 8, 41 (2017).
69.
Muniz Júnior RL, Godói IP, Reis EA et al. Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications. Expert Rev. Pharmacoecon. Outcomes Res. (2018) (Epub ahead of print).
70.
Minitab 17 Statistical Software. State College, PA, USA (2010).
71.
Human Development Report 1990. Published for the United Nations Development Programme (UNDP). Oxford University Press, NY, USA (1990).
72.
Instituto Brasileiro de Geografia e Estatística (IBGE) (2018). https://www.ibge.gov.br/home/
73.
Nascimento MC. Medicamentos: ameaça ou apoio à saúde? Vieira & Lent, Praia de Botafogo, Brazil, 200 (2003).
74.
Bortolon PC, Karnikowski MG, de Assis M. Self-medication versus pharmaceutical indication: the pharmacy professional in the primary care health of elderly. www.ufjf.br/nates/files/2009/12/12automedicacao1.pdf
75.
Cameron A, Roubos I, Ewen M, Mantel-Teewisse AK, Leufkens HGM, Lainkg RO. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull. World Health Org. 89, 412–421 (2011).
76.
Oliveira MA, Luiza VL, Tavares NUL et al. Access to medicines for chronic diseases in Brazil: a multidimensional approach. Rev. Saúde Publica 50(Suppl. 2), 6s (2016).
•• Key paper discussing access to medicines for chronic diseases in Brazil.
77.
Zucchi P, Nero C, Malik A. Health expenditures: demand and supply factors in health services. Saúde e Sociedade 9(1/2), 127–150 (2000). www.mpgo.mp.br/portalweb/hp/2/docs/gastos_saude_fatores_demanda.pdf
78.
Brasil. Ministério da Saúde Brasília MINISTÉRIO DA SAÚDE. Lei nº 13.021, de 8 de agosto de(2014). www.planalto.gov.br/ccivil_03/_Ato2011-2014/2014/Lei/L13021.htm
79.
Brasil. MINISTÉRIO DA SAÚDE. ORGANIZAÇÃO PAN-AMERICANA DA SAÚDE. ORGANIZAÇÃO MUNDIAL DA SAÚDE. Avaliação da assistência farmacêutica no Brasil: estrutura, processo e resultados. MS, Brasília (2005). www.paho.org/bra/index.php?option=com_docman&task=doc_view&gid=744&Itemid=965
Information & Authors
Information
Published In
Pages: 1027 - 1041
PubMed: 31512925
Copyright
© 2019 Future Medicine Ltd.
History
Received: 23 February 2019
Accepted: 30 May 2019
Published online: 12 September 2019
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Indicator of access to medicines in relation to the multiple dimensions of access. (2019) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2019-0031
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Samuel Baker Obakiro, Ronald Kibuuka, Brenda Nakazibwe, Andrew Marvin Kanyike, Francis Mawejje, Maureen Namugaya, Steven Nsereko Muwanga, Richard Maseruka, Catherine Nabitandikwa, Kenedy Kiyimba, Dan Kibuule, Xinyang Jiang, Congzhou Chen, Paul Waako, Guanqiao Li, Essential medicines out of reach: a cross-sectional study of community-level access in Eastern Uganda, BMC Health Services Research, 10.1186/s12913-026-14145-6, 26, 1, (2026).
- F Chuliber, A Gutiérrez, E Kordys, E Rossi, V Romañano, E Lobo, B Horrach, V Castoldi, A Martí, Disponibilidad y distribución de los recursos de hemostasia y trombosis en Argentina en el año 2022, Revista Hematología, 10.48057/hematologa.v28i1.577, 28, 1, (2024).
- Carlien Schmidt, Moliehi Matlala, Brian Godman, Amanj Kurdi, Johanna C. Meyer, Perceptions of and Preparedness for the Application of Pharmacoeconomics in Practice, among Final Year Bachelor of Pharmacy Students in South Africa: A National Cross-Sectional Study, Pharmacy, 10.3390/pharmacy11020054, 11, 2, (54), (2023).
- Hlalanathi Mbonane, Mncengeli Sibanda, Brian Godman, Johanna C. Meyer, Moliehi Matlala, Knowledge, attitudes and practices of healthcare professionals on the use of an electronic stock visibility and management tool in a middle-income country: Implications for access to medicines, Exploratory Research in Clinical and Social Pharmacy, 10.1016/j.rcsop.2023.100233, 9, (100233), (2023).
- Mariana M Barbosa, Thais A Moreira, Renata CRM Nascimento, Mariana MG Nascimento, Francisco A Acurcio, Brian Godman, Augusto A Guerra, Juliana Alvares-Teodoro, Access to medicines in the Brazilian Unified Health System’s primary health care: assessment of a public policy, Journal of Comparative Effectiveness Research, 10.2217/cer-2021-0026, 10, 10, (869-879), (2021).
- Khezar Hayat, Zia Ul Mustafa, Brain Godman, Muhammad Arshed, Jiaxing Zhang, Faiz Ullah Khan, Fahad Saleem, Krizzia Lambojon, Pengchao Li, Zhitong Feng, Yu Fang, Perceptions, Expectations, and Experience of Physicians About Pharmacists and Pharmaceutical Care Services in Pakistan: Findings and Implications, Frontiers in Pharmacology, 10.3389/fphar.2021.650137, 12, (2021).
- Maria Rubio-Valera, Silvia Marqués-Ercilla, M Teresa Peñarrubia-María, Rosa M. Urbanos-Garrido, Carme Borrell, Jordi Bosch, Alba Sánchez-Viñas, Ignacio Aznar-Lou, Who Suffers From Pharmaceutical Poverty and What Are Their Needs? Evidence From a Spanish Region, Frontiers in Pharmacology, 10.3389/fphar.2021.617687, 12, (2021).
- Wenderson Henrique Rocha, Juliana Álvares Teodoro, Francisco de Assis Acurcio, Augusto Afonso Guerra, Isabel Cristina Gomes Moura, Brian Godman, Amanj Kurdi, Renata Cristina Rezende Macedo do Nascimento, Alessandra Maciel Almeida, Influence of pharmaceutical services organization on the availability of essential medicines in a public health system, Journal of Comparative Effectiveness Research, 10.2217/cer-2020-0259, 10, 6, (519-532), (2021).
- Mariana M Barbosa, Renata CRM Nascimento, Marina M Garcia, Francisco A Acurcio, Brian Godman, Augusto A Guerra, Juliana Alvares-Teodoro, Strategies to improve the availability of medicines in primary health care in Brazil: findings and implications, Journal of Comparative Effectiveness Research, 10.2217/cer-2020-0125, 10, 3, (243-253), (2021).
- Patrick Githendu, Linden Morrison, Rosemary Silaa, Sai Pothapregada, Sarah Asiimwe, Rafiu Idris, Tatjana Peterson, Emma Davidson, Abaleng Lesego, Neema Mwale, Sako Mayrick Mwakalobo, Laurean Rugambwa Bwanakunu, Tom Achoki, Transformation of the Tanzania medical stores department through global fund support: an impact assessment study, BMJ Open, 10.1136/bmjopen-2020-040276, 10, 11, (e040276), (2020).